- Gossypin
-
- $176.00
-
2026-07-17
- CAS:652-78-8
- Purity: 99.90%
- Supply Ability: 10g
- Gossypin
-
- $890.00
-
2024-04-02
- CAS:652-78-8
- Min. Order: 1g
- Purity: 97
- Supply Ability: 500 Kg
|
| | GOSSYPIN Basic information |
| Product Name: | GOSSYPIN | | Synonyms: | 3,3',4',5,7,8-HEXAHYDROXYFLAVONE 8-GLUCOSIDE;3,3',4',5,7-PENTAHYDROXY-8-O-GLUCOSYLFLAVONE;GOSSYPIN;,7-trihydroxy-;2-(3,4-dihydroxyphenyl)-8-(beta-d-glucopyranosyloxy)-3,5,7-trihydroxy-4h-1-b;4h-1-benzopyran-4-one,2-(3,4-dihydroxyphenyl)-8-(beta-d-glucopyranosyloxy)-3,5;gossypin from hibiscus vitifolius*flowers;gossypetin-8-glucoside | | CAS: | 652-78-8 | | MF: | C21H20O13 | | MW: | 480.38 | | EINECS: | | | Product Categories: | Flavanols | | Mol File: | 652-78-8.mol |  |
| | GOSSYPIN Chemical Properties |
| Melting point | 229-230°C | | Boiling point | 886.0±65.0 °C(Predicted) | | density | 1.883±0.06 g/cm3 (20 ºC 760 Torr) | | storage temp. | -20°C | | solubility | DMSO: soluble15mg/mL, clear | | form | powder | | pka | 5.70±0.40(Predicted) | | color | light yellow to dark green-yellow | | Major Application | food and beverages | | InChIKey | SJRXVLUZMMDCNG-KKPQBLLMSA-N | | SMILES | OC[C@H]1O[C@@H](Oc2c(O)cc(O)c3C(=O)C(O)=C(Oc23)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O | | LogP | -1.320 (est) |
| Hazard Codes | Xi,Xn | | Risk Statements | 36/37/38-62-37/38-36-22 | | Safety Statements | 26-36-37 | | WGK Germany | 3 | | RTECS | DJ3009900 | | HS Code | 2938909090 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | GOSSYPIN Usage And Synthesis |
| Uses | antiinflammatory, antiangiogenesis, antineoplastic, inhibits NF-kB cell response | | Definition | ChEBI: A glycosyloxyflavone that is gossypetin attached to a beta-D-glucopyranosyl residue at position 8 via a glycosidic linkage. | | Biological Activity | Gossypin is an anti-inflammatory pentahydroxyflavone glucoside isolated from Hibiscus vitifolius th at is used as an herbal remedy for diabetes, jaundice, and inflammation. Gossypin potently inhibits human cancer cell proliferation, including melanoma and glioma cells. Gossypin directly binds and inhibits BRAFV600E and CDK4 kinases, and also regulates Chk1 and Cdc25C in U251 glioma cells. | | in vivo | Gossypin (10-20 mg/kg; p.o.; 30 days) attenuates Isoprenaline (ISO) (HY-108353)-induced ischemic/reperfusion (I/R) in rats via alteration of oxidative stress, inflammatory reaction and gut microbiota[2].
| Animal Model: | Sprague Dawley (SD) rats (200-225 g; male; 8-10 weeks)[2] | | Dosage: | 10, 20 mg/kg | | Administration: | Oral gavage (p.o.); 30 days | | Result: | Reduced the infarct size induced by Isoprenaline (ISO) (HY-108353).
Showed the boosted level of LVESP, SW, ESPVR, DP, EDPVR and suppressed level of LVEDP.
Increased the bodyweight and suppressed the heart weight and heart/body weight ratio.
Suppressed the level of triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and increased the level of high-density lipoprotein (HDL).
Suppressed the level of nitric oxide synthase (iNOS) and nitric oxide (NO).
Decreased the level of MMP-2 and MMP-9.
Suppressed the level of inflammatory cytokines (TNF-α, IL-1β, IL-6) and decreased the level of NF-κB in the serum and heart tissue.
Suppressed the apoptosis of muscle fibres with edema and necrosis.
|
|
| | GOSSYPIN Preparation Products And Raw materials |
|